Home › Cancro del polmone non a piccole cellule › Oregon › Portland
Studi clinici su Cancro del polmone non a piccole cellule a Portland, OR
46 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Portland e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · a 12 mi di distanza
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
In reclutamentoFase 1/2
- Oregon Health & Science University (OHSU), Portland
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #51, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
In reclutamentoFase 1
- Site 02, Portland
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
In reclutamentoFase 1
- ALX Center 6, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- PHN-012-001 Site, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
In reclutamentoFase 1
- Research Site, Portland
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- OHSU Knight Cancer Institute, Northwest, Portland
- Providence Cancer Institute Franz Clinic, Portland
- OHSU Knight Cancer Institute, East Portland, Portland
- e altri 6
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
In reclutamentoFase 3
- Oregon Health and Science University ( Site 0052), Portland
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
In reclutamentoFase 2
- Providence Cancer Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Northwest Cancer Specialists, P.C., Portland
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Oregon Health And Science University, Portland
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Oregon Health And Science University, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
In reclutamentoFase 1
- Research Site, Portland
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- e altri 1
Pan-tumor MRD Study
In reclutamentoStudio osservazionale
- Oregon Health & Science University (OHSU), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
In reclutamentoFase 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Oregon Health and Science University, Portland
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
In reclutamentoFase 3
- Clinical Study Site, Portland
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
In reclutamentoFase 3
- Providence Cancer Institute, Portland
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
In reclutamentoFase 2/3
- Local Institution - 007-885B, Portland
- Local Institution - 007-885A, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
In reclutamentoFase 1
- Providence Cancer Institute, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Oregon Health and Science University, Portland
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
In reclutamentoFase 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
In reclutamentoFase 1/2
- Compass Oncology - Rose Quarter, Portland
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
In reclutamentoFase 1/2
- Providence Cancer Institute, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
In reclutamentoFase 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- e altri 1
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
In reclutamentoFase 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
In reclutamentoFase 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- e altri 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 2
- USA15-0, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- e altri 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- e altri 1
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
In reclutamentoFase 2
- Providence Health & Services - Oregon, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- e altri 2
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Kaiser Permanente Northwest, Portland
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
In reclutamentoFase 1
- Providence Cancer Institute, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
In reclutamentoFase 1/2
- Oregon Health & Science University, Portland
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Altri studi a Portland
- Cancro (tutti i tipi)34 studi
- Cancro al seno33 studi
- Cancro alla prostata33 studi
- Cancro metastatico29 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Cancro ai polmoni26 studi
- Leucemia mieloide acuta25 studi
- Cancro dell'endometrio24 studi
- Carcinoma a cellule squamose della testa e del collo19 studi
- Cancro pancreatico19 studi
- Insufficienza cardiaca17 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.